Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion
Authors:
- 1 September 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 198 (5) , 675-678
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell HistiocytosisJAMA Oncology, 2018
- Current understanding and management of pulmonary Langerhans cell histiocytosisThorax, 2017
- Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomesJCI Insight, 2017
- Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosisBlood, 2016
- Mutually exclusive extracellular signal‐regulated kinase pathway mutations are present in different stages of multi‐focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the diseaseHistopathology, 2016
- RecurrentNRASmutations in pulmonary Langerhans cell histiocytosisEuropean Respiratory Journal, 2016
- Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester DiseaseJournal of Clinical Oncology, 2015
- Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesisBlood, 2014
- Cladribine Is Effective against Cystic Pulmonary Langerhans Cell HistiocytosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010